SPRUCE BIOSCIENCES INC has a total of 27 patent applications. Its first patent ever was published in 2018. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are NANJING BAIJINGYU PHARMACEUTICAL CO LTD, KING CLIFFORD RILEY and ALGERNON PHARMACEUTICALS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | Australia | 3 | |
#4 | Brazil | 3 | |
#5 | Canada | 3 | |
#6 | EPO (European Patent Office) | 3 | |
#7 | China | 2 | |
#8 | Republic of Korea | 2 | |
#9 | Argentina | 1 | |
#10 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Heterocyclic compounds | |
#3 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Howerton Alexis | 23 |
#2 | Gerber Hal | 23 |
#3 | Huang Michael | 10 |
#4 | Karaborni Sami | 9 |
#5 | Alexis Howerton | 3 |
#6 | Hal Gerber | 3 |
#7 | Ghosh Sangita | 2 |
#8 | Sami Karaborni | 1 |
#9 | Barnes Christopher | 1 |
#10 | Michael Huang | 1 |
Publication | Filing date | Title |
---|---|---|
WO2021016208A1 | Methods of treating congenital adrenal hyperplasia | |
US2020255436A1 | Corticotropin releasing factor receptor antagonists | |
AU2019260793A1 | Methods for treating testicular and ovarian adrenal rest tumors | |
BR112020002966A2 | corticotropin releasing factor receptor antagonists | |
WO2019036503A1 | Corticotropin releasing factor receptor antagonists |